In keeping with ACR rules, allopurinol is strongly encouraged as a primary-line urate-reducing medication. Genetic screening is usually recommended (for the variant called HLA B*5801) previous to starting allopurinol because the carriers of this gene are at an increased danger of the intense allergic response.As being a provider to our audience, Ha